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The characterization of the new lineage of IL-17-producing CD4+ T helper (Th17) cells has revolutionized our
current understanding of T cell-mediated immunity. Over the past five years, there have beenmany twists and
turns as the pathways that lead to Th17 cell differentiation have been elucidated. Not least of these was the
discovery that TGF-b is a crucial cytokine for Th17 cell development, suggesting that Th17 and regulatory
T cell subsets share reciprocal developmental pathways during the pathogenesis or control of inflammation.
This review aims to bring together the observations that have formed current opinion on factors that promote
and contain Th17 cell development, in both mouse and man. Unresolved controversies in this field are also
discussed: For example, IL-23 is absolutely required for disease pathogenesis in many models of Th17-cell-
mediated autoimmunity, yet its role in Th17 cell development is relatively unclear.Discovery of the Th17 Cell Subset—A Brief History
The recent advances in our understanding of the development of
Interleukin (IL)-17-producing CD4+ effector T cells (Th17 cells)
have led to a substantial revision of the T helper subset hypoth-
esis. In 1986, a cornerstone of modern T cell biology was laid
down by Mossman and Coffman when they published two land-
mark papers that proposed the Th1-Th2 hypothesis (Coffman
and Carty, 1986; Mosmann et al., 1986). The theory was based
on the observation that distinct subsets of CD4+ T helper (Th)
cells expressed discrete cytokine profiles that defined their func-
tion: Th1 cells induce cell-mediated inflammatory responses,
and Th2 cells provide B cell help. Importantly, Coffman predi-
cated that the effector cytokines produced by one subset of cells
would regulate the development and function of the other. This
concept has been validated over the past decades by molecular
and genetic studies demonstrating a complex network of cross-
regulating Janus kinase (JAK) and signal transducer and activa-
tor of T cells (STAT) signaling pathways as well as transcriptional
regulators such as T-bet and GATA-3 that coordinate genetic
programming of the differentiating T cells.
The Th1-Th2 hypothesis has served the immunology commu-
nity well, particularly in understanding infectious and allergic dis-
eases. Nevertheless, this model does not fit all systems; there
are many inconsistencies when it comes to the study of organ-
specific autoimmune diseases. Th1-cell-mediated responses
can certainly play an important role in the initiation of autoanti-
gen-specific inflammation, exemplified by T cell passive-transfer
studies. However, depletion of critical Th1-specific factors often
gave contradictory results. For example, interferon (IFN)-g, the
hallmark Th1mediator that is critical for antitumor and antimicro-
bial responses, has paradoxical roles during chronic inflamma-
tion. Injection of IL-12 or IFN-g blocked experimental autoim-
mune encephalomyelitis (EAE) (Gran et al., 2004; Voorthuis
et al., 1990), whereas genetic or antibody-mediated depletion
of IFN-g enhanced disease (Billiau et al., 1988; Willenborg
et al., 1999), suggesting that Th1-cell-produced factors might
in fact regulate chronic inflammation. Deletion of the Th1 path-
way molecules IL-12(p35), IL-12Rb2, IFN-gR, and STAT1 has
further supported the role of Th1 cells in regulating rather than
promoting many models of autoimmunity (Bettelli et al., 2004;Gran et al., 2002; Zhang et al., 2003). Despite these observa-
tions, immunologists (including ourselves) continued to maintain
that autoimmune diseases are predominantly driven by auto-
reactive Th1 cells.
In 2000, IL-23 was described as the pairing of the p19 subunit
with the p40 subunit, also shared with IL-12 (Oppmann et al.,
2000); thus began the study of the relative contribution of IL-12
and IL-23 to chronic inflammatory diseases. On the basis of
the observation that IL-12 receptor b2 is expressed in naive
T cells, whereas IL-23 receptor is only found in memory-acti-
vated T cells (Parham et al., 2002), it seemed likely that because
IL-12 is an important factor for Th1 cell development, subse-
quent exposure to IL-23 might be required for maturation of
effector cells. This led to the hypothesis that these two related
cytokines would initiate and then sustain Th1-cell-mediated
immune responses, which were consistent with the observation
that both the IL-12p40- and IL-23p19-deficient mice were resis-
tant to Th1-associated autoimmune diseases (Cua et al., 2003).
However, thorough analysis of the CNS-infiltrating cells in EAE-
resistant Il23a/ mice showed the presence of neuroantigen-
specific IFN-g secreting Th1 cells (albeit in low numbers) (Langr-
ish et al., 2005). In addition, Il12a/ mice, which lack IL-12 but
express functional IL-23, have few IFN-g secreting cells—yet
these mice suffer from a hyperacute form of EAE (Cua et al.,
2003; Gran et al., 2002). These unexpected findings suggested
that IL-23 may regulate the function of a hitherto unknown
population of inflammatory cells and prompted the search for
an IL-23-dependent cell population capable of inducing chronic
inflammation.
In 2003, Gurney and colleagues showed that IL-23 promotes
the production of IL-17 by activated T cells (Aggarwal et al.,
2003). Around the same time, Langrish, Murphy, and colleagues
established that IL-23 is a key cytokine that induced expansion
of IL-17-producing CD4+ T cells and that autoimmune resistant
Il23a/ mice have very few cells capable of secreting IL-17
(Langrish et al., 2005; Murphy et al., 2003). IL-17 was known
as a proinflammatory cytokine that mediates multiple chronic
inflammatory responses including angiogenesis, recruitment of
inflammatory cells, and induction of proinflammatory mediators
by endothelial and epithelial tissues (reviewed in this issue ofImmunity 28, April 2008 ª2008 Elsevier Inc. 445
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proposal that IL-23 is required for the development and/or ex-
pansion of inflammatory IL-17-producing cells (Langrish et al.,
2005; Murphy et al., 2003). On the basis of the characteristic
cytokine profile, these cells were subsequently called ThIL-17
or Th17 (Langrish et al., 2005; McKenzie et al., 2006; Weaver
et al., 2006). Gene-expression analysis of the IL-17-producing
cells showed a distinct gene-expression profile compared to
Th1 cells (Langrish et al., 2005). IL-23-driven cells expressed
high amounts of IL-17A, IL-17F, and Tumor necrosis factor
(TNF)a. In contrast, IL-12 specifically promoted expression of
IFN-g, granzyme F, granzyme G, TNF-related apoptosis-induc-
ing ligand (TRAIL), B lymphocyte stimulator (BLYS), and Fas
ligand. These differences predicted that Th1 and Th17 cells
probably have distinct immune functions.
The concept that Th17 cells are responsible for driving auto-
immune inflammation was finally established when it was shown
that EAE was induced by passive transfer of IL-17-producing
memory activated CD4+ T cells (Langrish et al., 2005). In addi-
tion, both IL-12 and IFN-gwere found to suppress IL-17 produc-
tion (Langrish et al., 2005; Murphy et al., 2003), and the lack of
this suppression in IL-12- or IFN-g-deficient micemay contribute
to EAE exaceration. Two additional landmark studies further
showed that both Th1- and Th2-cell-specific transcriptional
regulators (STAT1 and T-bet, STAT6 and GATA3, respectively)
inhibited Th17 cell differentiation (Harrington et al., 2005; Park
et al., 2005). Thus, as predicted by Mossman and Coffman, ef-
fector cytokines produced by distinct T cell subsets governed
the development and function of another. Collectively, these ini-
tial studies ushered in the concept of the Th17 hypothesis and
began to change thewaywe viewed T cell biology and inflamma-
tory diseases.
RORgt Is the Th17-Cell-Specific Transcription Factor
After the observation that Th17 cells expressed a distinct subset
of cytokines and chemokines compared to Th1 and Th2 cells, we
performed an Affymetrix gene-expression analysis and found
a number of Th17-cell-specific factors with potential DNA bind-
ing activities. In collaboration with Dan Littman’s group, we con-
firmed that Rorc—which encodes RORgt, a retinoid orphan
nuclear receptor—is specifically expressed in both human and
mouse Th17 cells (Ivanov et al., 2006; Wilson et al., 2007). The
Th17 cells for this analysis were initially derived by stimulation
of activated T cells with IL-23. Subsequent experiments showed
that stimulation of naive T cells with transforming growth factor
(TGF)-b and IL-6 (see below) also enhanced RORgt mRNA ex-
pression. Expression of RORgt in naive T cells was both
necessary and sufficient to induce IL-17A, IL-17F, and IL-23R
expression (Ivanov et al., 2006). Furthermore, Rorc/ mice
are unresponsive to IL-23 stimulation, have reduced number of
Th17 cells, and are resistant to autoimmune diseases. More re-
cently, Dong and colleagues further demonstrated that RORa
synergizes with RORgt to promote differentiation and function
of Th17 cells (Yang et al., 2008). Thus, Rora-Rorc double-mutant
mice harbor few Th17 cells and may be more resistant to inflam-
matory diseases. Upregulation of RORgt is STAT3 dependent,
and maximal IL-17 production also appears to require functional
STAT4 (Harris et al., 2007; Mathur et al., 2007; Yang et al.,
2007)—the signaling pathways involved in Th17 cell differentia-446 Immunity 28, April 2008 ª2008 Elsevier Inc.tion are fully discussed in the review by O’Shea and Murray
(2008) in this issue.
Cytokines that Regulate Th17 Cell Differentiation
in Mice
One major issue with the Th17 hypothesis in the early days was
the lack of clarity for the initial regulation of Th17 cell lineage
commitment. IL-23 was initially shown to induce IL-17 produc-
tion in activated T cells, and because IL-23R is not expressed
on naive T cells, it is not surprising that it was difficult to demon-
strate direct induction of de novo Th17 cells by IL-23. However,
two papers from Dong and colleagues and Weaver and
colleagues suggested that this was possible if IFN-g and
IL-4 were blocked (Harrington et al., 2005; Park et al., 2005).
In early 2006, three research groups demonstrated that TGF-b
acting in the presence of proinflammatory cytokines, particu-
larly IL-6, is sufficient to induce naive T cell differentiation into
Th17 cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen
et al., 2006a) (Figure 1A). Importantly, stimulation of naive T cells
with TGF-b and IL-6 also enhanced RORgt mRNA expression
(Ivanov et al., 2006). These studies led to the general acceptance
that IL-23 does not directly enhance the effects of TGF-b and
may not be required during the initial differentiation of Th17
cells in the presence of TGB-b and IL-6. The role of IL-23 will
be discussed later.
Previously, TGF-b had been associated primarily with anti-
inflammatory effects, particularly because it is intricately in-
volved in the induction, maintenance, and function of Foxp3+
Treg cells that are generated in the thymus (natural nTreg cells)
and induced in the periphery (inducible iTregs cells) (reviewed
in this issue by Li and Flavell [2008]). It was already known that
IL-6 inhibited the suppressive function of nTreg cells (Pasare
and Medzhitov, 2003). The surprise was that the presence of
IL-6 along with TGF-b, provided either exogenously or by nTreg
cells present in the culture, resulted in upregulation of IL-17 in
naive T cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen
et al., 2006a). In this context, IL-6most probably serves two func-
tions. First, IL-6 favors Th17 cell induction while inhibiting Treg
cells: Korn et al. showed that IL-6-deficient mice are resistant
to EAE in part because of their propensity to expand Treg cells
rather than Th17 cells after immunization (Korn et al., 2007). Sec-
ond, IL-6 upregulates factors in naive T cells that are probably
important for further development of the Th17 cell phenotype:
IL-23R and IL-21 (Ivanov et al., 2006; Zhou et al., 2007).
The in vivo source of TGF-b during Th17 cell differentiation is
not clear. Several lines of evidence suggest that Foxp3+ Treg
cells may be involved in the differentiation of Th17 cells through
the provision of TGF-b. In vitro, dendritic cells (DCs) stimulated
with certain microbial components such as curdlan and lipopoly-
saccharide (LPS) are capable to induce Th17 cells, but this
requires an exogenous source of TGF-b, which can be provided
by the presence of Treg cells in the culture (LeibundGut-Land-
mann et al., 2007; Veldhoen et al., 2006a). In contrast, zymosan
and Mycobacterium tuberculosis appear to induce sufficient
TGF-b from DC to negate this requirement for Treg cells in vitro
(Veldhoen et al., 2006b). However, Th17 cells are notably absent
in mice that lack TGF-b production only in CD4+ T cells (Li et al.,
2007), even after immunization with adjuvant containing Myco-
bacterium, further suggesting that T cell sources of TGF-b are
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nevertheless not clarified whether Treg cells are the important
contributor of TGF-b.
In contrast to IL-6, IL-2 is required for iTreg cell generation and
nTreg cell survival (Davidson et al., 2007; Setoguchi et al., 2005;
Zheng et al., 2007a) but is dispensible for, and in fact inhibits,
Th17 cell differentiation (Laurence et al., 2007). Hence, IL-2-defi-
cient mice have large numbers of Th17 cells but are deficient in
peripheral Treg cells, and they suffer severe lymphoproliferative
immunopathology. This is perhaps surprising, given the depen-
denceofother helperTcell subsetson IL-2, andsuggests that ad-
ditional factor(s) substitute for IL-2 during Th17 cell development.
One candidate is IL-21, another member of the common gamma
chain cytokine family along with IL-2. IL-21 is produced by Th17
cells upon stimulation by IL-6 and by IL-21 itself, although other
subsetsof T cellsmayalsoproduce IL-21; it is also thought topro-
mote B cell responses (IL-21 functions are reviewed by Ouyang
et al. [2008]). IL-21 acts in an autocrine manner to promote
Th17 cell differentiation along with TGF-b, and may even be
able to compensate for absent IL-6 for induction of RORgt and
Th17 cell differentiation (Korn et al., 2007; Nurieva et al., 2007;
Zhou et al., 2007). Although it is clear that IL-21 enhances the
rate of Th17 cell conversion, itmay not be essential for the lineage
commitment of Th17 cells or their pathogenic functions.
Much like IL-2, retinoic acid has recently been shown to pro-
mote Foxp3+ Treg cell induction over Th17 cell induction by
TGF-b, even in the presence of IL-6. Retinoic acid binds retinoic
Figure 1. Th17 Cell Differentiation in Mouse and Man
(A) In mouse, naive T cells activated in the presence of TGF-b (possibly pro-
vided by Treg cells) and IL-6 begin differentiation toward the Th17 cell subset;
IL-6 upregulates IL-21 and IL-23R to further their Th17 development. In the ab-
sence of IL-6, TGF-b instead induces regulatory T cells. Th17 cell development
is inhibited by Th1 and Th2 cytokines, as well as IL-2 and retinoic acid.
(B) In man, IL-23 or IL-1 drives differentiation of Th17 cells that express IL23R
and CCR6. IL-1’s effects may be enhanced by IL-23 and/or IL-6. Th1-cell-
promoting cytokines inhibit Th17 cell development.acid receptor (RAR) to directly induce Foxp3 expression and in-
hibits RORgt expression and IL-17 production (Elias et al., 2008;
Mucida et al., 2007; Schambach et al., 2007) (Figure 1A). In the
intestine and draining mesenteric LN, CD103+ dendritic cells
have been shown to metabolize dietary beta carotene (vitamin
A) to secrete retinoic acid (Coombes et al., 2007). These
CD103+ DCs also produce TGF-b and are strong inducers of
Foxp3+ regulatory T cells but poor inducers of Th17 cells unless
retinoic acid is inhibited. In contrast, CD103 DCs produce IL-6,
TNFa, and IL-23 but low amounts of TGF-b, and they are poor
Treg cell inducers. Thus, in the context of TGF-b, retinoic acid
and IL-6 may be key switch factors that promote the balance be-
tween Treg cell and Th17 cell development in the gut mucosa.
The finding that retinoic acid is produced by DCs in this site
may explain why the Th17 cell population is limited despite rela-
tively high amounts of IL-6 in the intestinal tract. Treg cells are
clearly important in maintaining tolerance in the intestine, but
the role of Th17 cells in this site is less clear. Th17 cells have
been isolated from the gut mucosa of patients with active
Crohn’s disease and are found in some mouse models of colitis
(Annunziato et al., 2007; Kullberg et al., 2006; Yen et al., 2006).
On the other hand, depletion of IL-17 exacerbated inflammation
in the DSSmodel of colitis in mice (Ogawa et al., 2004), suggest-
ing that IL-17 may have a protective and/or reparative role in the
intestine after exposure to toxins or pathogens. The cellular
source of this ‘‘protective’’ IL-17 has yet to be determined
because many cell types, including myeloid cells (Kullberg
et al., 2006), can produce IL-17.
Much as the Th1 and Th2 cell subsets crossregulate the differ-
entiation of the other, they also appear to negatively regulate
differentiation of Th17 cells. Addition of IL-12, IFN-g, or IL-4 to
cultures inhibits either IL-23- or TGF-b plus IL-6-stimulated dif-
ferentiation of mouse and human Th17 cells (Annunziato et al.,
2007; Harrington et al., 2005; Murphy et al., 2003; Park et al.,
2005; Wilson et al., 2007). It is not clear for how long developing
Th17 cells are susceptible to this regulation. One paradox in this
regard is the observations frommany investigators that a subset
of Th17 cells may coproduce IFN-g. This is particularly apparent
when looking at T cells from sites of inflammation, for example,
the brain of mice after EAE induction (Chen et al., 2006;
McGeachy et al., 2007) or the intestine of patients with active
Crohn’s disease (Annunziato et al., 2007). This suggests that
IFN-g cannot always downregulate IL-17 production and may
in fact contribute to the pathogenic function of Th17 cells,
although this has not been thoroughly investigated. In relation
to this point, it is interesting to note that mice lacking the Th1
transcription factor T-bet produce greater numbers of IL-17+
cells (Park et al., 2005), presumably because of reduced IFN-g
production, yet these mice are also extremely resistant to
Th17-cell-mediated models of inflammation, including EAE (Bet-
telli et al., 2004). It is still not clear whether the important contri-
bution of T-bet in these models is toward the function of Th17
cells, Th1 cells, or to other cells such as DCs. T-bet may be ex-
pressed in Th17 cells stimulated with IL-23 (Chen et al., 2006),
and T-bet has been suggested to positively regulate IL-23R
expression (Gocke et al., 2007). However, because IL-6 also
stimulates IL-23R upregulation in the presence of TGF-b, which
represses T-bet, it does not seem likely that this fully explains the
requirement for T-bet in Th17 cells.Immunity 28, April 2008 ª2008 Elsevier Inc. 447
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Although there is general agreement on the factors required for
the generation of murine Th17 cells, the crucial initiating cyto-
kines for human Th17 cell development remain less clear.
Four groups have recently found that the combination of TGF-b
plus IL-6 does not drive IL-17-producing T cells in vitro (Acosta-
Rodriguez et al., 2007a; Chen et al., 2007; van Beelen et al.,
2007; Wilson et al., 2007); in fact, TGF-b inhibited production
of IL-17 (Acosta-Rodriguez et al., 2007a; Wilson et al., 2007).
However, although there are similarities, these investigators
did not quite reach a common consensus as to the factors
that are required or sufficient to drive the Th17 cell phenotype
in human T cells. Chen et al. showed that IL-23 was able to drive
Th17 cell differentiation, and Wilson et al. found that culture with
either IL-23 or IL-1 stimulated the Th17 cell phenotype, with little
or no synergy when both cytokines were present. In contrast,
Acosta-Rodriguez et al. identified IL-1 as driving human Th17
cells in vitro, with IL-23 and IL-6 able to potentiate the effects
of IL-1 (Figure 1B). Thus, there are some outstanding questions
remaining when it comes to the differentiation of human Th17
cells. It seems that the controversy of whether TGF-b has any
role to play in their development has not yet been fully laid to
rest. The description of IL-21 as an autocrine growth factor
and its potential to couple TGF-b in the generation of murine
Th17 cells further raises the notion that as-yet-unrecognized
cytokines may have important functions in human Th17 differ-
entiation.
Although their differentiation may not be identical, the pheno-
type of human Th17 cells does bear many similarities to murine
Th17 cells. Both subsets produce IL-17, IL-17F, and IL-22 as
hallmark cytokines. Expression of the IL-23R (Annunziato et al.,
2007; Wilson et al., 2007) and the chemokine receptor CCR6
(Acosta-Rodriguez et al., 2007b; Annunziato et al., 2007; Hirota
et al., 2007; Lim et al., 2008; Singh et al., 2008) additionally define
this subset. It appears that IFN-g production by Th17 cells can
be even further segregated in humans on the basis of chemokine
receptor expression: CCR6+CCR4+ cells produce exclusively
IL-17, whereas CCR6+CXCR3+ cells coproduce IL-17 and IFN-g
(Acosta-Rodriguez et al., 2007b). Human Th17 cells may also
produce IL-26 (Wilson et al., 2007), whereas murine pathogenic
Th17 cells have been shown to produce TNFa and IL-6 (Langrish
et al., 2005).
Stimuli that Promote Th17-Cell-Inducing Dendritic Cells
As the cytokines that promote Th17 cell differentiation have been
delineated, so have the microbial factors and pathways that
stimulate the Th17-cell-inducing phenotype in DC. IL-17 is
important in the control or clearance of various pathogens
(reviewed by Ouyang et al. [2008] and Umemura et al. [2007]).
These include the extracellular bacteria Klebsiella pneumonia
(Ye et al., 2001), Citrobacter rodentium (Mangan et al., 2006),
and Borrelia Burgdorferi (Infante-Duarte et al., 2000), as well as
systemic infection with the fungal pathogen Candida albicans
(Huang et al., 2004). Candida-specific Th17 cell responses
have also been observed in peripheral blood of human donors
(Acosta-Rodriguez et al., 2007b). Th17 cells do not appear to
be required for clearance of Mycobacterium infection but may
facilitate recruitment of Th1 cells to the lungs and thus aid the re-
sponse (Khader et al., 2007). An important point to bear in mind448 Immunity 28, April 2008 ª2008 Elsevier Inc.when considering effects of absence of IL-17 signaling is that
IL-17 can also be produced aspart of the innate immune response.
Several adjuvants including LPS and CpG promote some
Th17-cell-promoting cytokines such as IL-23 and IL-6 produc-
tion from DCs, but these components also induce strong IL-12
responses and therefore promote Th1 cell responses as well
as low amounts of IL-17 (LeibundGut-Landmann et al., 2007).
However, the Saccharomyces cerevisiae cell-wall component
zymosan, as well as Mycobacteria, which both contain ligands
for TLR2 but do not signal exclusively through this pathway, pro-
mote strong Th17 cell responses inmurine cell culture and in vivo
(Veldhoen et al., 2006b). Mycobacterium tuberculosis is the key
ingredient of complete Freund’s adjuvant (CFA), the widely
used adjuvant for murine immunizations; although CFA was
long thought to induce Th1 cell responses, it is now clear that
it also very effectively induces Th17 cell responses. This is asso-
ciated with the capacity to strongly induce IL-6 and IL-23 as well
as TGF-b, allowing the differentiation of naive T cells into Th17
cells without the requirement for addition of exogenous TGF-b
as was required for LPS-induced Th17 cells (Veldhoen et al.,
2006a). The source of antigen presenting cell (APC) may also in-
fluence the response elicited: Acosta-Rodriguez and colleagues
found that monocytes from human PBMC produced large
amounts of IL-1 and IL-6 but not IL-12 in response to various
TLR stimulants including LPS and peptidoglycan and were
therefore good inducers of Th17 cells. However, generation of
dendritic cells by culture of monocytes with IL-4 resulted in cells
that produced greater amounts of IL-12 in response to these
stimulants and were therefore poor inducers of the Th17 cell
phenotype (Acosta-Rodriguez et al., 2007a).
b-glucan components in zymosan also signal through TLR-
independent pathways to promote Th17 cell induction (Gantner
et al., 2003). Fungal b-glucans, including Curdlan, bind to the
C type lectin Dectin-1 on dendritic cells and trigger IL-23 produc-
tion (LeibundGut-Landmann et al., 2007). These Dectin-1-acti-
vated DCs also produce proinflammatory cytokines including
TNFa and IL-6 and upregulate costimulatory molecules such
as CD80 and CD40. However, in contrast to TLR-stimulated
DCs, Dectin-1 stimulated DCs do not produce substantial
amounts of IL-12 and appear to preferentially induce Th17 over
Th1 cell responses. An additional TLR-independent pathway
for generation of Th17-promoting DC is the ligation of the intra-
cellular receptor NOD2 by muramyldipeptide (MDP)—a break-
down product of internalized peptidoglycan (van Beelen et al.,
2007). The signaling pathways for NOD2 and Dectin-1 may
converge in their shared use of caspase recruitment domain
(CARD) 9.
Interestingly, peptidoglycan joins zymosan as one of the few
microbial components that can be substituted for Mycobacteria
during the induction of autoimmune inflammation in the mouse
model of EAE (Visser et al., 2005). It is likely that the common
factor is the triggering of Th17-cell-promoting pathways in
DCs by these pathogen components, although this has not
been investigated for peptidoglycan. In humans, the link
between infection and autoimmune disease remains intriguing
yet elusive. However, the discovery of pathogens that preferen-
tially promote Th17 cell responses and their corresponding abil-
ity to promote Th17-cell-mediated autoimmune inflammation in
murine models is very suggestive. Further compelling examples
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Borrelia burgdorferi, the causative agent of Lyme’s disease,
can lead to subsequent development of arthritis, and in mice,
this is dependent on IL-17 (Burchill et al., 2003). Fungal b-glu-
cans have also been found to trigger onset of arthritis via dec-
tin-1 receptor activation in genetically susceptible SKG mice
(bearing a mutation in the SH2 domain of ZAP70) (Yoshitomi
et al., 2005).
Th17 Cells in Immunopathology
It is now clear that IL-23 and IL-17 are associated with a number
of human autoimmune disorders, validating the findings in
mouse models (IL-17 functions are more extensively reviewed
byOuyang et al. [2008]). One of the earliest human disease asso-
ciations for IL-17 was demonstrated in rheumatoid arthritis (RA).
Lebecque and coworkers showed that IL-17 induced human
synovial cells to produce IL-6, IL-8, and TNF, suggesting that
IL-17 may directly act on stromal cells to promote inflammation
(Fossiez et al., 1996; Kotake et al., 1999). In addition, Th17 cells
found in human arthritic synovium expressed receptor activator
of nuclear factor kappa B ligand (RANKL), which is a potent cy-
tokine that promotes formation of bone resorptive osteoclasts
(Kim et al., 2007). These observations suggest that Th17 cells
are likely to be highly pathogenic in RA. Likewise, IL-17+ CD4+
andCD8+ T cells have been identified in active lesions in the brain
from multiple sclerosis (MS) patients (Tzartos et al., 2008). Prat
and colleagues elegantly demonstrated that receptors for IL-17
and IL-22 are present on inflamed endothelium in MS lesions
and that these cytokines may potentiate migration of inflamma-
tory T cells across the blood-brain barrier (Kebir et al., 2007).
Psoriasis is another immune-mediated inflammatory disease
that has been linked to inappropriate Th17 cell responses. The
Th17 factors RORgt, IL-17, IL-22, and IL-23 mRNA are all ele-
vated in psoriatic lesional skin (Lee et al., 2004; Teunissen
et al., 1998; Wilson et al., 2007; Wolk et al., 2004). Anti-p40 treat-
ment—which inhibits both IL-12 and IL-23—was highly effica-
cious for treatment of psoriasis (Krueger et al., 2007). Future clin-
ical studies using anti-p19 will determine whether IL-23 is the
target of choice for treatment of this skin inflammatory disease.
Currently, one of the most powerful tools for studying human
diseases is genome-wide disease-association analysis. Using
this strategy, Cho and colleagues screened 547 patients and
case-control cohorts and identified IL-23R as an inflammatory-
bowel-disease gene (Duerr et al., 2006). A number of IL-23R sin-
gle-nucleotide polymorphisms (SNPs) including Arg381Gln were
found to be highly associated with IBD. This study underscores
the critical importance of IL-23 signaling in regulation of chronic
tissue inflammation. At this point, it is not clear whether it is gain
of function or loss of function that lead to human IBD. Additional
genetic studies have since shown that IL-23R polymorphism is
also linked to psoriasis, psoriatic arthritis, ankylosing spondylitis,
andmultiple-sclerosis-disease susceptibility (Burton et al., 2007;
Capon et al., 2007; Cargill et al., 2007; Illes et al., 2008; Smith
et al., 2007). Together, these studies demonstrate that IL-23
and/or IL-23R are potential targets for treatment of chronic in-
flammatory disorders such as psoriasis and Crohn’s disease.
In addition, because IL-17 is clearly involved in joint inflammation
and bone erosion, it is probably an effective therapeutic target
for treatment of RA.TGF-b-IL-6 Promotes IL-10: A Self-Regulating
Mechanism for Th17 Cells?
Regulation of robust adaptive T cell responses is crucial for pre-
venting host tissue damage during clearance of infectious path-
ogens and most probably also during periods of remission from
autoimmune disease. In this regard, IL-10 has long been known
to be important for regulation of Th1 cell responses to patho-
gens. However, it was only recently shown that the Th1 effector
cells are themselves important coproducers of IL-10 with IFN-g,
and thus ‘‘self-regulate’’ (Anderson et al., 2007; Jankovic et al.,
2007). IL-27 production by activated DCs promotes IL-10 pro-
duction in Th1 cells and may therefore be an important mediator
of this type of regulation (Awasthi et al., 2007; Fitzgerald et al.,
2007; Stumhofer et al., 2007).
Our lab and others have recently demonstrated that Th17 cells
generated in the presence of TGF-b plus IL-6 include a subset of
cells that produce IL-10 along with IL-17 (McGeachy et al., 2007;
Stumhofer et al., 2007). Unlike Th1 cells, IL-27 was found to in-
hibit the generation of Th17 cells but promote IL-10 (Stumhofer
et al., 2007). Hence, although IL-27 is known to regulate the se-
verity of Th17 cell responses, the mechanisms may be different
to Th1 cell regulation.
While investigating the regulation of effector Th17 cells, we
found that restimulation of activated Th17 cells in the presence
of TGF-b and IL-6 also resulted in IL-10 production concomitant
with increased IL-17 (McGeachy et al., 2007). Analogous to the
Th1 cell situation, this T cell-produced IL-10 was able to regulate
Th17 cell immunopathology, which was demonstrated by re-
duced disease severity after cotransfer of TGF-b-plus-IL-6-stim-
ulated T cells with IL-23-stimulated (pathogenic) T cells. Hence,
we proposed that continued exposure of differentiating Th17
cells to TGF-b and IL-6 results in regulation through production
of IL-10, as well as other mechanisms (Figure 2). Just as Th1 cells
that produce IL-10 are not considered regulatory T cells, we do
not consider these cells ‘‘regulatory Th17 cells’’ but rather that
this IL-10 production may be a mechanism of self-regulation of
the otherwise potentially dangerous Th17 cell response. Impor-
tantly, IL-23 does not maintain the IL-10 induced by TGF-
b plus IL-6 but also does not directly inhibit IL-10 production.
Hence, stimulation with IL-23 results in gain of pathogenic
function, whereas continued exposure to TGF-b may self-limit
the response even in the presence of IL-23, and the balance of
signals will determine the outcome of the response.
There is an unresolved question over whether Treg cells can
suppress Th17 cells, but there are suggestions that in contrast
to IFN-g, IL-17 production and/or Th17 cell development may
not be downregulated by Treg cells in vitro (Annunziato et al.,
2007; O’Connor et al., 2007). Defective Treg cell function or num-
bers has been associated with several autoimmune diseases
that are now also Th17-cell-associated (Baecher-Allan and
Hafler, 2004). Also, there is some debate over whether DCs or
T cells are more pivotal targets for Treg cells. Our studies with
TGF-b and IL-6 activation of effector cells suggested that al-
though IL-17may not be downregulated, the outcome of interac-
tions between Treg cells and effector Th17 cells could in fact be
regulation of the inflammatory response. However, the issue of
whether Treg cells can effectively inhibit Th17 cell responses
has yet to be fully clarified. In any case, it appears that continued
strong proinflammatory signals in the presence of TGF-b plusImmunity 28, April 2008 ª2008 Elsevier Inc. 449
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ReviewIL-6 will trigger mechanisms of self-regulation in Th17 cells to
limit bystander immunopathology.
What Is the Role of IL-23 in Th17 Cell Biology?
The findings that TGF-bplus IL-6 alonemaynot be sufficient to in-
duce the full pathogenicTh17cell phenotypecoupledwith theob-
servations in IL-23-deficient mice raise again the question: What
is the bona fide function of IL-23 in Th17 cell biology?Because IL-
23 is not required for initial IL-17 induction in vitro, and the IL-23R
is not expressed on naive T cells, the early proposals that IL-23
directly drives differentiation of the Th17 cell lineage (Harrington
et al., 2005; Langrish et al., 2005; Park et al., 2005) have been
predominantly discounted. Several alternative suggestions for
the function of IL-23 have been put forth, and even started to
gain acceptance, but we feel the evidence is still inconclusive.
The most commonly presumed function of IL-23 is to expand
differentiated Th17 cells or maintain IL-17 production, two over-
lapping ideas based on similar data. These conclusions were
reached after in vitro observations that the presence of IL-23 dur-
ing culture of activated cells results in increased proliferation of
activated T cells (Oppmann et al., 2000) and increased frequen-
cies of IL-17+ cells (Langrish et al., 2005) or that IL-23 was re-
quired during restimulation of TGF-b plus IL-6-stimulated cells
to maintain their IL-17 production (Veldhoen et al., 2006a). In
a similar vein, it has also been suggested that IL-23 may stabilize
the phenotype of Th17 cells through STAT3-dependent mecha-
nisms (Yang et al., 2007; Zhou et al., 2007), although IL-6 and
IL-21 also share the STAT3 signaling pathway with IL-23. Finally,
an alternative hypothesis for the current data is that IL-23 is a
survival factor for Th17 cells (Elson et al., 2007).
Although all of these suggestions broadly concur with the re-
duced frequencies of IL-17+ cells generated in IL-23-deficient
mice, they have yet to be convincingly supported in vivo, and
these functions of IL-23 may not provide a full picture. In addi-
tion, they do not incorporate the findings that IL-23 can promote
expression of additional pathogenic factors in Th17 cells, includ-
ing IL-22, that are required for disease pathogenesis in certain
models includingpsoriasis (Lianget al., 2006;Zhengetal., 2007b).
Figure 2. Regulation of Th17 Cell Responses by TGF-b- and IL-6-
Induced IL-10
Continued stimulation of activated murine Th17 cells with TGF-b and IL-6
results in enhancement of IL-17 and IL-10. In contrast, IL-23 only enhances
IL-17. The balance of cells stimulated under each condition will ultimately de-
termine whether the Th17 cell response is regulated or leads to severe tissue
damage, as depicted by the sliding scale on the right.450 Immunity 28, April 2008 ª2008 Elsevier Inc.In the Citrobacter rodentium model described by Mangan
et al., IL-17+ cells were observed in Il23a/mice but were unable
to clear the infection (Mangan et al., 2006). The mechanisms for
this observation were not investigated, but one explanation could
bea requirement for IL-23 topromote the effector functionof Th17
cells.However, it is alsoclear that IL-23canpromote inflammatory
functions in cells of the innate immune system (Cua et al., 2003;
Uhlig et al., 2006) (Michel et al., 2007); therefore, the results
obtained in IL-23-deficient animals need to be interpreted
with care.
Rather than expanding or stabilizing pre-existing Th17 cells,
could IL-23 in fact have an earlier role during their differentiation
in vivo? IL-23R expression is upregulated remarkably early in
response to IL-6 (within 1 to 2 days [Zhou et al., 2007], making
it possible that IL-23 begins to act quite early during Th17 cell
differentiation. These findings suggest that IL-23 may be more
central to differentiation of effector Th17 cells than is currently
appreciated, and it might not merely expand or enhance survival
of pathogenic Th17 cells.
Summary and Future Perspectives
Over the past few years, there have been remarkable advances
in our understanding of the regulation of T cell responses during
immune homeostasis and disease pathogenesis. The key areas
of discovery have been identification of the cytokines and tran-
scriptional regulators that control the function of distinct T cell
subsets. We now recognize that specific cytokines can induce
activation of transcriptional factors such as T-bet, GATA3,
RORgt, and Foxp3, which control the development and function
of Th1, Th2, Th17, and Treg cells, respectively. However, there
are still many unknowns. Although in vitro studies suggest that
T cells follow a strict developmental program when activated
with discrete cytokines, in vivo T cells are actually exposed to
a complex cytokine milieu and display considerable plasticity.
For example, many of the CD4+ T cells isolated from an inflamed
central nervous system during EAE do not exclusively belong to
either the Th1 or Th17 cell subsets as currently defined because
they coproduce IL-17 and IFN-g. For many years, the presence
of Th1 cell signature cytokines implicated Th1 cells in many of
the diseases that are now associated with Th17 cells, raising
the possibility that inflammatory autoimmune diseases are not
necessarily restricted to just Th1 or Th17 cell type responses.
The possible synergistic or antagonistic interactions between
these subsets in vivo need to be more fully clarified.
The studyof humanTh17cell differentiation and function is only
in its infancy, and there remains much to know about how the
cells that drive inflammation in human diseases are generated.
Although human genetic evidence suggests that targeting IL-23
or IL-23R may benefit IBD patents, more work is also needed to
understand the precise function of this potent immune regulator.
Whether IL-23 is important in the generation or expansion of
pathogenic Th17 cells and the relative contribution of IL-23 to
activation of inflammatory myeloid cells are still unclear. Careful
analysis of the in vivo expression of IL-23R and the fate of
IL-23R-deficient cells should help to finally resolve these issues.
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